The Israeli government is in talks to acquire the Pfizer-produced coronavirus vaccine, which the American drugmaker said Monday is more than 90% effective in preventing COVID-19.
Pfizer, which developed its experimental vaccine with German partner BioNTech, announced on Monday promising findings following phase 3 of the clinical trial. An initial analysis indicated an efficacy rate of more than 90% among participants without evidence of a prior COVID-19 infection.